CRVO - CervoMed Inc.

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 6.92

Open

$ 7.11

Bid

$ 6.55 x 60

Ask

$ 7.45 x 1

Day's Range

$ 6.77 - $ 7.27

52 Week Range

$ 1.80 - $ 16.94

Volume

46,898

Average Volume

Market Cap

64.03M

Beta (5Y Monthly)

$ -0.17

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-07-2025	09-30-2025	10-Q
2	08-08-2025	06-30-2025	10-Q
3	05-12-2025	03-31-2025	10-Q
4	03-17-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-09-2024	06-30-2024	10-Q
7	05-14-2024	03-31-2024	10-Q
8	03-29-2024	12-31-2023	10-K
9	11-13-2023	09-30-2023	10-Q
10	08-08-2023	06-30-2023	10-Q
11	05-15-2023	03-31-2023	10-Q
12	03-24-2023	12-31-2022	10-K
13	11-14-2022	09-30-2022	10-Q
14	08-12-2022	06-30-2022	10-Q
15	05-12-2022	03-31-2022	10-Q
16	03-18-2022	12-31-2021	10-K
17	11-10-2021	09-30-2021	10-Q
18	08-11-2021	06-30-2021	10-Q
19	05-07-2021	03-31-2021	10-Q
20	03-17-2021	12-31-2020	10-K
21	11-12-2020	09-30-2020	10-Q
22	08-07-2020	06-30-2020	10-Q
23	05-11-2020	03-31-2020	10-Q
24	03-17-2020	12-31-2019	10-K
25	11-08-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	03-19-2019	12-31-2018	10-K
29	11-13-2018	09-30-2018	10-Q
30	08-10-2018	06-30-2018	10-Q
31	05-10-2018	03-31-2018	10-Q
32	04-02-2018	12-31-2017	10-K
33	11-13-2017	09-30-2017	10-Q
34	08-14-2017	06-30-2017	10-Q
35	05-15-2017	03-31-2017	10-Q
36	03-31-2017	12-31-2016	10-K
37	11-14-2016	09-30-2016	10-Q
38	08-15-2016	06-30-2016	10-Q
39	05-16-2016	03-31-2016	10-Q
40	03-25-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-docebo-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-wednesday

This Docebo Analyst Begins Coverage On A B...
11/05/2025 13:48:58

this-trex-company-analyst-turns-bearish-here-are-top-5-downgrades-for-wednesday

This Trex Company Analyst Turns Bearish; H...
11/05/2025 12:22:37

this-sarepta-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday

This Sarepta Therapeutics Analyst Turns Bu...
11/05/2025 11:44:29

HC Wainwright & Co. Upgrades CervoMed to B...
11/05/2025 11:35:54

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades CervoMed (NASDAQ:CRVO) from Neutral to Buy and raises the price ...

D. Boral Capital Maintains Buy on CervoMed...
11/04/2025 13:41:57

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.

CervoMed Announces FDA Alignment On Key As...
11/04/2025 12:12:50

cervomed-drug-cut-dementia-progression-risk-by-75-in-trial

CervoMed Drug Cut Dementia Progression Ris...
10/08/2025 15:54:18

CervoMed's Phase 2b trial shows neflamapimod reduces dementia progression and plasma GFAP, with significant cognitive impro...

CervoMed Shares Additional Data From Phase...
10/08/2025 11:03:59

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB...

CervoMed Highlights Dementia Drug Results ...
09/17/2025 11:42:08

CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (Ce...

HC Wainwright & Co. Reiterates Neutral on ...
09/08/2025 10:55:36

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Neutral and announces $11 price ...

D. Boral Capital Maintains Buy on CervoMed...
08/18/2025 11:45:07

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $31.

Roth Capital Reiterates Buy on CervoMed, L...
08/12/2025 17:32:23

Roth Capital analyst Boobalan Pachaiyappan reiterates CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $20...

Chardan Capital Maintains Buy on CervoMed,...
08/11/2025 11:46:25

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $15 price target.

CervoMed Q2 EPS $(0.70) Misses $(0.63) Est...
08/08/2025 13:57:44

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.63) by...

Canaccord Genuity Maintains Buy on CervoMe...
07/29/2025 15:42:13

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $21 t...

cervomeds-dementia-data-show-slowed-disease-progression

CervoMed's Dementia Data Show Slowed Disea...
07/28/2025 15:20:34

CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good to...

D. Boral Capital Maintains Buy on CervoMed...
07/28/2025 12:11:05

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $10 price target.

12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

CervoMed Shares Resume Trading; Up 60% Fol...
07/28/2025 11:42:42

CervoMed Announces 32-Week Extension Resul...
07/28/2025 11:02:38

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% ...